GO:0036316 SREBP-SCAP complex retention in endoplasmic reticulum

The sterol regulatory element binding protein (SREBP) and SREBP-cleavage-activating protein (SCAP) form a complex that senses cellular sterol levels and controls lipid synthesis. Under sterol-rich conditions, this complex is retained in the endoplasmic reticulum (ER) through interactions with ER-resident proteins, a process formally known as SREBP-SCAP complex retention in the endoplasmic reticulum (GO:0036316). This retention prevents SREBP from reaching the Golgi apparatus, where it would otherwise be proteolytically activated to drive cholesterol and fatty acid synthesis. Understanding this regulatory step is crucial because it directly influences cholesterol homeostasis and membrane lipid composition. Erlins, a family of ER proteins, have been shown to restrict SREBP activation and regulate cellular cholesterol homeostasis, highlighting the importance of ER retention mechanisms. Additionally, the SCAP gene is directly regulated by the androgen receptor through an androgen response element in intron 8, connecting hormonal signaling to SREBP processing. These findings underscore the integration of sterol sensing with broader cellular signaling pathways. Researchers studying lipid metabolism, metabolic disorders, and cancer are increasingly focused on the molecular players that mediate SREBP-SCAP retention. This article provides a comprehensive overview of GO:0036316, covering its definition, key genes, regulatory mechanisms, disease relevance, and experimental approaches for investigation.

GO:0036316, SREBP-SCAP complex retention in endoplasmic reticulum, is a biological process that maintains the SREBP-SCAP complex within the ER and prevents it from moving to other cellular compartments. In the absence of sterols, the complex is packaged into COPII vesicles and travels to the Golgi for processing. In the presence of sterols, the complex binds ER-resident proteins such as INSIG, which retain it in the ER.

SREBP-SCAP complex retention in the endoplasmic reticulum is a critical checkpoint in lipid metabolism. It ensures that cholesterol and fatty acid synthesis are suppressed when sterols are plentiful, preventing lipotoxicity and maintaining membrane integrity. Dysregulation of this process is linked to metabolic disorders, cancer, and cardiovascular diseases. Moreover, the interaction between SCAP and androgen receptor signaling highlights its broader role in hormone-responsive tissues.

The following genes and proteins are central to SREBP-SCAP complex retention in the endoplasmic reticulum.

The retention of the SREBP-SCAP complex in the ER is primarily regulated by sterol levels. Cholesterol and oxysterols bind to SCAP, inducing a conformational change that promotes INSIG binding and ER retention. Additionally, Erlins modulate this process by forming ER membrane complexes that restrict SREBP activation. Hormonal signals, such as androgens acting through the androgen receptor, can regulate SCAP gene expression via an androgen response element in intron 8, thereby influencing the availability of SCAP for complex formation.

Dysregulation of SREBP-SCAP retention leads to excessive lipid synthesis, contributing to hypercholesterolemia, fatty liver disease, and atherosclerosis. Erlins, which help retain the complex, are implicated in maintaining cholesterol homeostasis, and their dysfunction may exacerbate these conditions.

Many cancers exhibit elevated SREBP activity to support rapid proliferation. Loss of ER retention mechanisms can lead to constitutive SREBP activation, promoting lipogenesis and tumor growth. Targeting the retention pathway is a potential therapeutic strategy.

The androgen receptor directly regulates SCAP transcription through an intron 8 enhancer, linking androgen signaling to lipid metabolism. This connection may be relevant in prostate cancer and other androgen-dependent pathologies.

Genome-wide CRISPR knockout screens can identify genes that, when lost, cause constitutive SREBP activation. Cells expressing a SREBP-responsive reporter are infected with a sgRNA library, and sorted for altered reporter activity. Hits are validated by individual KO and lipid profiling.

Affinity purification coupled to mass spectrometry (AP-MS) of SCAP or INSIG can reveal dynamic interactions under different sterol conditions. Proximity labeling (BioID) can capture transient ER retention complexes.

Fluorescence microscopy of GFP-tagged SCAP or SREBP allows real-time visualization of ER-to-Golgi transport. Retention can be quantified by colocalization with ER markers (e.g., calnexin) versus Golgi markers (e.g., GM130).

Luciferase reporters driven by SREBP target promoters (e.g., HMGCR, LDLR) measure SREBP activity. Sterol depletion or overexpression of retention factors can modulate reporter output.

Researchers studying SREBP-SCAP complex retention in endoplasmic reticulum-related genes often need to determine whether a candidate gene is causally involved in sterol sensing, ER retention, or lipid homeostasis. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.

GO:0036316, SREBP-SCAP complex retention in the endoplasmic reticulum, is a fundamental regulatory process that controls lipid homeostasis by preventing premature SREBP activation. Its dysregulation is implicated in metabolic diseases and cancer, making it a promising target for therapeutic intervention. Understanding the molecular players, such as SCAP, INSIG, and Erlins, provides insights into sterol sensing and ER retention mechanisms. The androgen receptor's regulation of SCAP adds another layer of complexity, linking hormone signaling to lipid metabolism.